|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM284493724 |
| 003 |
DE-627 |
| 005 |
20231225043338.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.05.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0948.xml
|
| 035 |
|
|
|a (DE-627)NLM284493724
|
| 035 |
|
|
|a (NLM)29803820
|
| 035 |
|
|
|a (PII)S1521-6616(17)30858-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yu, Yun-Zhou
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Improved synaptic and cognitive function in aged 3 × Tg-AD mice with reduced amyloid-β after immunotherapy with a novel recombinant 6Aβ15-TF chimeric vaccine
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.08.2019
|
| 500 |
|
|
|a Date Revised 27.08.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018. Published by Elsevier Inc.
|
| 520 |
|
|
|a Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder impairing memory and cognition. In this study, we describe the immunogenicity and protective efficacy of the novel recombinant 6Aβ15-TF chimeric antigen as a subunit protein vaccine for AD. Recombinant 6Aβ15-TF chimeric vaccine induced strong Aβ-specific humoral immune responses without Aβ-specific T cell immunity in C57/BL6 and 3 × Tg-AD mice at different ages. As an early immunotherapy model for AD, this vaccine induced high titers of long-lasting anti-Aβ42 antibodies in aged 3 × Tg-AD mice, which led to improve behavioral performance and markedly reduced the levels of insoluble and soluble Aβ and Aβ oligomers. In agreement with these findings, immunotherapy with 6Aβ15-TF prevented the Aβ-induced decrease of presynaptic and postsynaptic proteins in aged 3 × Tg-AD mice. Our results suggest that this novel and highly immunogenic recombinant 6Aβ15-TF chimeric vaccine provides neuroprotection in AD mice and can be considered an effective AD candidate vaccine
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Alzheimer's disease
|
| 650 |
|
4 |
|a Amyloid-β
|
| 650 |
|
4 |
|a Calpain
|
| 650 |
|
4 |
|a Chimeric vaccine
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a Synaptic proteins
|
| 650 |
|
7 |
|a Alzheimer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Amyloid beta-Peptides
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a amyloid beta-protein (1-42)
|2 NLM
|
| 700 |
1 |
|
|a Li, Qing-Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Hai-Chao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Si
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pang, Xiao-Bin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Qing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Xiao-Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Pei-Tang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 193(2018) vom: 01. Aug., Seite 12-23
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:193
|g year:2018
|g day:01
|g month:08
|g pages:12-23
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.05.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 193
|j 2018
|b 01
|c 08
|h 12-23
|